Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 18/20 | 0.63 |
| ▸ | KYAT3 | Q6YP21 | 4/20 | 0.59 |
| ▸ | KYAT1 | Q16773 | 3/20 | 0.59 |
| ▸ | GOT1 | P17174 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9886183 | 1.00 | AADAT (0.63) | AADATKYAT3KYAT1GOT1HTR2A | |
| SCHEMBL9108718 | 1.00 | AADAT (0.63) | AADATKYAT3KYAT1GOT1HTR2A | |
| SCHEMBL16612916 | 0.89 | AADAT (0.63) | AADATKYAT3KYAT1GOT1 | |
| SCHEMBL3779058 | 0.89 | AADAT (0.63) | AADATKYAT3KYAT1GOT1 | |
| SCHEMBL10036785 | 0.83 | HTR2A (0.47) | AADATKYAT3KYAT1GOT1HTR2A | |
| SCHEMBL10036787 | 0.83 | HTR2A (0.47) | AADATKYAT3KYAT1GOT1HTR2A | |
| SCHEMBL10036778 | 0.83 | HTR2A (0.47) | AADATKYAT3KYAT1GOT1HTR2A | |
| SCHEMBL10067844 | 0.80 | AADAT (0.43) | AADATKYAT3KYAT1GOT1HTR2A | |
| SCHEMBL6763386 | 0.78 | AADAT (0.74) | AADATKYAT3KYAT1GOT1 | |
| SCHEMBL2127331 | 0.78 | AADAT (0.68) | AADATKYAT3KYAT1GOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103228631-B | Kat II inhibitors | PFIZER | 2015-04-29 | — | — | CN | disclosed |
| EP-2646417-A1 | KAT II INHIBITORS | Pfizer Inc (US) | 2013-10-09 | — | — | EP | disclosed |
| CN-103228631-A | Kat II inhibitors | PFIZER | 2013-07-31 | — | — | CN | disclosed |
| US-8487104-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487104-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487104-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2012073146-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012073146-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142729-A1 | KAT ll INHIBITORS | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142729-A1 | KAT ll INHIBITORS | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142729-A1 | KAT ll INHIBITORS | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142729-A1 | KAT ll INHIBITORS | KAT7, KAT2A, KATNA1 | AADAT 1043/4885KYAT3 90/4885KYAT1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.